These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1397750)

  • 1. Safety experience from long-term treatment with omeprazole.
    Joelson S; Joelson IB; Lundborg P; Walan A; Wallander MA
    Digestion; 1992; 51 Suppl 1():93-101. PubMed ID: 1397750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical safety of omeprazole.
    Sölvell L
    Scand J Gastroenterol Suppl; 1989; 166():106-10; discussion 111-3. PubMed ID: 2690327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development programme for omeprazole.
    Walan A
    Digestion; 1990; 47 Suppl 1():54-8; discussion 76. PubMed ID: 2093016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.
    Brunner GH; Lamberts R; Creutzfeldt W
    Digestion; 1990; 47 Suppl 1():64-8; discussion 76. PubMed ID: 2093018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis.
    James OF; Parry-Billings KS
    Age Ageing; 1994 Mar; 23(2):121-6. PubMed ID: 8023719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
    Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis.
    Robinson M; Decktor DL; Maton PN; Sabesin S; Roufail W; Kogut D; Roberts W; McCullough A; Pardoll P; Saco L
    Aliment Pharmacol Ther; 1993 Feb; 7(1):67-73. PubMed ID: 8439639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
    Ohkusa T; Maekawa T; Arakawa T; Nakajima M; Fujimoto K; Hoshino E; Mitachi Y; Hamada S; Mine T; Kawahara Y; Nagai T; Aoyama N; Yoshida N; Tadokoro K; Chida N; Konda Y; Seno H; Shimatani T; Inoue M; Sato N
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1331-9. PubMed ID: 15932363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
    Richter JE; Sabesin SM; Kogut DG; Kerr RM; Wruble LD; Collen MJ
    Am J Gastroenterol; 1996 Sep; 91(9):1766-72. PubMed ID: 8792695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic effect of low-dose omeprazole vs. standard-dose ranitidine in mild to moderate reflux esophagitis].
    Kim JW; Kim HS; Lee DK; Suk KT; Kim JM; Baik SK; Kwon SO; Cho MY
    Korean J Gastroenterol; 2004 Mar; 43(3):153-9. PubMed ID: 15034285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemolytic anemia associated with the use of omeprazole.
    Marks DR; Joy JV; Bonheim NA
    Am J Gastroenterol; 1991 Feb; 86(2):217-8. PubMed ID: 1992636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with omeprazole: assessment of efficacy and safety.
    Walan A
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative tolerability profile of omeprazole in clinical trials.
    Simon TJ; Bradstreet DC
    Dig Dis Sci; 1991 Oct; 36(10):1384-9. PubMed ID: 1914759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of reflux oesophagitis resistant to H2-receptor antagonists.
    Klinkenberg-Knol EC; Meuwissen SG
    Digestion; 1989; 44 Suppl 1():47-53. PubMed ID: 2575061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.